Want to see RARE full AI Analyst Report?
RARE Stock Chart & Stats
$26.46
-$0.16(-0.59%)
At close: 4:00 PM EDT
$26.46
-$0.16(-0.59%)
Day’s Range― - ―
52-Week Range$13.81 - $39.89
Previous CloseN/A
Volume170.99K
Average Volume (3M)2.24M
Market Cap
$1.46B
Enterprise Value$4.31K
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 04, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding98,588,875
10 Day Avg. Volume2,697,439
30 Day Avg. Volume2,242,805
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-28.35
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.17Price Target Upside2.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)-4.01
Revenue Forecast (FY)$752.83M
Bulls Say, Bears Say
Bulls Say
Scaling Revenue And High Gross MarginsSustained top-line expansion and very high product gross margins indicate strong pricing power in specialty rare-disease markets, creating operating leverage potential as commercial scale grows.
Diversified Commercial Product BaseRevenue from multiple marketed therapies, indications and geographies reduces dependence on a single asset. Expanding treated-patient populations and reimbursement support a broader, more durable commercial platform.
GENGLYCOS FDA ApprovalThe approval adds Ultragenyx’s first gene therapy to its commercial portfolio and opens a new rare-disease revenue stream. Its root-cause approach and long-term follow-up may strengthen the company’s gene-therapy capabilities.
Bears Say
Persistent Losses And Cash BurnLarge operating losses and cash consumption show that commercial revenue currently does not fund the cost base. Continued investment may require external capital or successful launches before profitability is achieved.
Negative Equity And Leverage RiskNegative equity and the prior debt spike weaken financial flexibility and increase refinancing exposure. These constraints could limit investment capacity or require financing if cash burn persists longer than planned.
Dependence On Binary Pipeline OutcomesThe path to growth and profitability relies heavily on uncertain regulatory and clinical outcomes. Setrusumab’s setback demonstrates execution risk, while failures elsewhere could delay launches and extend funding needs.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $13.81 and its highest was $39.89 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $1.46B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 04, 2026 which is in 60 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.318.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -0.87.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 98,588,875 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -3.41%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.17 (2.67% Upside)
$27.17 (2.67% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 85.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $416.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Very Bearish
Bullish news 11%
Bearish news 89%
Bearish news 89%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
RARE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$27.17
▲(2.67% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
3.95% Insiders
19.35% Mutual Funds
39.44% Other Institutional Investors
17.36% Public Companies and Individual Investors